The Investor
02 Apr 2026, 18:12
AstraZeneca reported positive Phase III trial results showing that its immunotherapy combination significantly improves outcomes in early-stage liver cancer.
In the EMERALD-3 trial, the combination of Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolisation (TACE) achieved a statistically significant improvement in progression-free survival compared to TACE alone.
The treatment also demonstrated a trend toward improved overall survival, a key secondary endpoint, although further data are still being evaluated.
The regimen, known as STRIDE, combines dual immunotherapy with targeted therapy and a standard embolisation procedure, aiming to delay disease progression and recurrence in patients with unresectable hepatocellular carcinoma.
AstraZeneca stated that the safety profile was consistent with known data and that the results will be presented at a future medical meeting and submitted to global regulators.
The findings highlight the potential of earlier use of immunotherapy combinations to improve outcomes in liver cancer, a disease where many patients currently face progression within months after standard treatment.
In the EMERALD-3 trial, the combination of Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib, and transarterial chemoembolisation (TACE) achieved a statistically significant improvement in progression-free survival compared to TACE alone.
The treatment also demonstrated a trend toward improved overall survival, a key secondary endpoint, although further data are still being evaluated.
The regimen, known as STRIDE, combines dual immunotherapy with targeted therapy and a standard embolisation procedure, aiming to delay disease progression and recurrence in patients with unresectable hepatocellular carcinoma.
AstraZeneca stated that the safety profile was consistent with known data and that the results will be presented at a future medical meeting and submitted to global regulators.
The findings highlight the potential of earlier use of immunotherapy combinations to improve outcomes in liver cancer, a disease where many patients currently face progression within months after standard treatment.